0001415889-24-019829.txt : 20240719 0001415889-24-019829.hdr.sgml : 20240719 20240719203544 ACCESSION NUMBER: 0001415889-24-019829 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240718 FILED AS OF DATE: 20240719 DATE AS OF CHANGE: 20240719 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lizzul Paul F. CENTRAL INDEX KEY: 0001711462 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37985 FILM NUMBER: 241129064 MAIL ADDRESS: STREET 1: 30699 RUSSELL RANCH ROAD STREET 2: SUITE 140 CITY: WESTLAKE VILLAGE STATE: CA ZIP: 91362 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ANAPTYSBIO, INC CENTRAL INDEX KEY: 0001370053 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 203828755 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10770 WATERIDGE CIRCLE, SUITE 210 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-362-6295 MAIL ADDRESS: STREET 1: 10770 WATERIDGE CIRCLE, SUITE 210 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: ANAPTYSBIO INC DATE OF NAME CHANGE: 20080828 FORMER COMPANY: FORMER CONFORMED NAME: ANAPTYS BIOSCIENCES INC DATE OF NAME CHANGE: 20060724 4 1 form4-07202024_120740.xml X0508 4 2024-07-18 0001370053 ANAPTYSBIO, INC ANAB 0001711462 Lizzul Paul F. C/O ANAPTYSBIO, INC. 10770 WATERIDGE CIRCLE, SUITE 210 SAN DIEGO CA 92121 false true false false Chief Medical Officer 1 Common Stock 2024-07-18 4 M 0 1500 18.50 A 13118 D Common Stock 2024-07-18 4 S 0 1500 35 D 11618 D Common 18.50 2024-07-18 4 M 0 1500 0 D 2030-07-30 Common 1500 88500 D Reflects the acquisition of 1,500 shares acquired under the Company's ESPP. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2023. The stock option vests and becomes exercisable as to 25% of the shares subject to the option on July 31, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. In addition to the remaining options to purchase 88,500 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 297,610 shares of common stock, which options vest according to their terms. /s/ Eric Loumeau, Attorney-in-Fact 2024-07-19